https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:46:052025-09-09 08:46:05Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:46:052025-09-09 08:46:05Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025
https://www.optimumcomms.com/wp-content/uploads/2025/09/DeuterOncology.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:43:462025-09-09 08:43:46DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025
https://www.optimumcomms.com/wp-content/uploads/2025/09/Connecta_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:34:452025-09-09 08:34:45CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support
https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:34:182025-09-09 08:34:18Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:31:002025-09-09 08:31:00AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-09 08:27:462025-09-09 08:27:46Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
https://www.optimumcomms.com/wp-content/uploads/2025/05/Kaerus_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-08 08:02:522025-09-08 08:02:52Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
https://www.optimumcomms.com/wp-content/uploads/2025/09/Bluecell_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-04 09:13:582025-09-04 09:30:10Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-03 08:58:232025-09-03 09:00:43Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-03 08:09:252025-09-03 08:09:25ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-02 08:39:312025-09-02 08:41:37Novo Holdings co-leads Phasecraft’s $34 million Series B financing to bring quantum computing closer to solving real-world challenges
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-01 07:14:352025-09-01 09:07:31Advanced Medical Solutions Group plc – Notice of Interim Results
https://www.optimumcomms.com/wp-content/uploads/2025/08/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-08-28 09:10:572025-08-28 09:10:57Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-08-27 08:39:562025-08-27 08:40:52Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper
https://www.optimumcomms.com/wp-content/uploads/2025/07/HCRX_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-07-30 15:07:492025-07-30 15:26:55KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the Firm’s Health Care Franchise and Enhancing its Life Sciences Strategy
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-07-30 11:12:182025-07-30 11:14:04Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapiesWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
